Abstract
The relationship between plasma levels of pyridostigmine to clinical evaluation of muscle power was examined in nine patients with myasthenia gravis during treatment with pyridostigmine in doses of 60 to 1040 mg daily. Five of the nine subjects demonstrated a trend towards a positive correlation, but in only two of them was this statistically significant at p < 0.05. In addition, the presence or absence of a possible correlation between muscle power and plasma concentration was not related to the duration of the disease, additional prednisolone therapy or thymectomy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Calvey T. N., Chan K. Plasma pyridostigmine levels in patients with myasthenia gravis. Clin Pharmacol Ther. 1977 Feb;21(2):187–193. doi: 10.1002/cpt1977212187. [DOI] [PubMed] [Google Scholar]
- Chan K., Calvey T. N. Plasma concentration of pyridostigmine and effects in myastenia gravis. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):596–601. doi: 10.1002/cpt1977225part1596. [DOI] [PubMed] [Google Scholar]
- Chan K., Williams N. E., Baty J. D., Calvey T. N. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr. 1976 May 26;120(2):349–358. doi: 10.1016/s0021-9673(76)80012-x. [DOI] [PubMed] [Google Scholar]
- Cohan S. L., Dretchen K. L., Neal A. Malabsorption of pyridostigmine in patients with myasthenia gravis. Neurology. 1977 Mar;27(3):299–301. doi: 10.1212/wnl.27.3.299. [DOI] [PubMed] [Google Scholar]
- Cohan S. L., Pohlmann J. L., Mikszewski J., O'Doherty D. S. The pharmacokinetics of pyridostigmine. Neurology. 1976 Jun;26(6 Pt 1):536–539. doi: 10.1212/wnl.26.6.536. [DOI] [PubMed] [Google Scholar]
- Davison S. C., Hyman N., Prentis R. A., Dehghan A., Chan K. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man. Methods Find Exp Clin Pharmacol. 1980 Apr;2(2):77–82. [PubMed] [Google Scholar]
- Engel W. K. Myasthenia gravis, corticosteroids, anticholinesterases. Ann N Y Acad Sci. 1976;274:623–630. doi: 10.1111/j.1749-6632.1976.tb47720.x. [DOI] [PubMed] [Google Scholar]
- Grob D., Namba T. Characteristics and mechanism of neuromuscular block in myasthenia gravis. Ann N Y Acad Sci. 1976;274:143–173. doi: 10.1111/j.1749-6632.1976.tb47683.x. [DOI] [PubMed] [Google Scholar]
- Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol. 1977 Jan;7(1):36–43. doi: 10.1016/0090-1229(77)90027-7. [DOI] [PubMed] [Google Scholar]